JP2014526441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526441A5 JP2014526441A5 JP2014528614A JP2014528614A JP2014526441A5 JP 2014526441 A5 JP2014526441 A5 JP 2014526441A5 JP 2014528614 A JP2014528614 A JP 2014528614A JP 2014528614 A JP2014528614 A JP 2014528614A JP 2014526441 A5 JP2014526441 A5 JP 2014526441A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- fgf21
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 208000030159 metabolic disease Diseases 0.000 claims 12
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims 10
- 102000056713 human FGF21 Human genes 0.000 claims 10
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 9
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529641P | 2011-08-31 | 2011-08-31 | |
| US61/529,641 | 2011-08-31 | ||
| PCT/US2012/053216 WO2013033452A2 (en) | 2011-08-31 | 2012-08-30 | Method of treating or ameliorating type 1 diabetes using fgf21 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132449A Division JP2017226665A (ja) | 2011-08-31 | 2017-07-06 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014526441A JP2014526441A (ja) | 2014-10-06 |
| JP2014526441A5 true JP2014526441A5 (OSRAM) | 2015-10-29 |
Family
ID=46964016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528614A Pending JP2014526441A (ja) | 2011-08-31 | 2012-08-30 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
| JP2017132449A Pending JP2017226665A (ja) | 2011-08-31 | 2017-07-06 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132449A Pending JP2017226665A (ja) | 2011-08-31 | 2017-07-06 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140213512A1 (OSRAM) |
| EP (1) | EP2750695A2 (OSRAM) |
| JP (2) | JP2014526441A (OSRAM) |
| AU (1) | AU2012301769B2 (OSRAM) |
| CA (1) | CA2845357A1 (OSRAM) |
| MX (1) | MX2014002260A (OSRAM) |
| WO (1) | WO2013033452A2 (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2558115B1 (en) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
| EP2726511B1 (en) | 2011-07-01 | 2019-08-07 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| CN108524919A (zh) | 2012-05-17 | 2018-09-14 | 延伸生物科学股份有限公司 | 用于改进的药物递送的载体 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP2925775B1 (en) | 2012-11-28 | 2020-09-16 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| KR102724421B1 (ko) | 2012-12-27 | 2024-10-30 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| CN105828833A (zh) | 2013-10-21 | 2016-08-03 | 萨克生物研究学院 | 突变的成纤维细胞生长因子（fgf）1及使用方法 |
| KR102178945B1 (ko) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 암 모델 및 관련 방법 |
| SI3097122T1 (sl) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| WO2015148708A1 (en) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| JP6308699B2 (ja) * | 2014-09-08 | 2018-04-11 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
| CA2960912A1 (en) | 2014-09-16 | 2016-03-24 | Universitat Autonoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| WO2016048999A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf21 truncations and mutants and uses thereof |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| MY181181A (en) * | 2014-12-23 | 2020-12-21 | Novo Nordisk As | Fgf21 derivatives and uses thereof |
| EP3242945B1 (en) | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EP3355908A1 (en) * | 2015-10-01 | 2018-08-08 | Amgen Inc. | Treatment of bile acid disorders |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| AU2016344134A1 (en) | 2015-10-30 | 2018-05-31 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs |
| JP6728352B2 (ja) * | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| WO2017180988A2 (en) | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
| AU2017268469C1 (en) * | 2016-05-20 | 2025-01-02 | President And Fellows Of Harvard College | Gene therapy methods for age-related diseases and conditions |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| AU2017358289C1 (en) | 2016-11-10 | 2025-05-08 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| EP4470551A3 (en) | 2017-03-14 | 2025-02-26 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| US11560416B2 (en) | 2017-04-21 | 2023-01-24 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| CN107056925B (zh) | 2017-04-28 | 2022-01-14 | 中国科学院合肥物质科学研究院 | 人fgf21突变体、其制备方法及用途 |
| EP3630160A1 (en) * | 2017-05-24 | 2020-04-08 | Universitat Autònoma De Barcelona | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
| KR102765034B1 (ko) * | 2017-05-24 | 2025-02-11 | 유니버시타트 아우토노마 데 바르셀로나 | 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트 |
| SMT202400277T1 (it) | 2017-12-22 | 2024-09-16 | Novartis Ag | Trattamento di disturbi metabolici con varianti di fgf21 |
| CN116098989A (zh) | 2018-02-08 | 2023-05-12 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
| CN114853908B (zh) | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| WO2021139763A1 (zh) * | 2020-01-08 | 2021-07-15 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| WO2023284822A1 (en) | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| CN113980147B (zh) * | 2021-11-26 | 2023-07-28 | 中国药科大学 | 一种聚多肽与fgf21融合蛋白突变体及其应用 |
| JP2025531878A (ja) * | 2022-09-12 | 2025-09-25 | アケロ セラピューティクス，インコーポレイティド | Ｆｇｆ２１変異体ポリペプチド |
| IL319526A (en) | 2022-09-30 | 2025-05-01 | Extend Biosciences Inc | Long-acting parathyroid hormone |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| WO2003011213A2 (en) * | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| EP3090753A1 (en) | 2004-10-07 | 2016-11-09 | The Regents of The University of California | Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels |
| EP2068909B1 (en) * | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| KR101651703B1 (ko) * | 2008-10-10 | 2016-08-26 | 암젠 인크 | Ｆｇｆ21 돌연변이체 및 이의 용도 |
| UY38740A (es) * | 2009-05-05 | 2020-12-31 | Amgen Inc | Mutantes de fgf21 y usos del mismo |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2010148142A1 (en) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
| EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
| EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
-
2012
- 2012-08-30 JP JP2014528614A patent/JP2014526441A/ja active Pending
- 2012-08-30 AU AU2012301769A patent/AU2012301769B2/en active Active
- 2012-08-30 EP EP12766746.7A patent/EP2750695A2/en not_active Withdrawn
- 2012-08-30 CA CA2845357A patent/CA2845357A1/en not_active Abandoned
- 2012-08-30 MX MX2014002260A patent/MX2014002260A/es unknown
- 2012-08-30 US US14/241,848 patent/US20140213512A1/en not_active Abandoned
- 2012-08-30 WO PCT/US2012/053216 patent/WO2013033452A2/en not_active Ceased
-
2017
- 2017-07-06 JP JP2017132449A patent/JP2017226665A/ja active Pending
- 2017-08-08 US US15/671,923 patent/US20180000898A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526441A5 (OSRAM) | ||
| JP2014511863A5 (OSRAM) | ||
| JP6312765B2 (ja) | 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物 | |
| JP2012041342A5 (OSRAM) | ||
| JP2012525844A5 (OSRAM) | ||
| JP2010202664A5 (OSRAM) | ||
| CN107636009B (zh) | 具有改善的稳定性的胰高血糖素衍生物 | |
| JP2010031018A5 (OSRAM) | ||
| ES2953631T3 (es) | Agonistas del receptor de GLP-1/glucagón en el tratamiento de la enfermedad de la esteatosis hepática y la esteatohepatitis | |
| JP2017501381A5 (OSRAM) | ||
| CA2862516A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP2017531613A5 (OSRAM) | ||
| JP2016516016A5 (OSRAM) | ||
| JP2011528333A5 (OSRAM) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2014513952A5 (OSRAM) | ||
| JP2015508771A5 (OSRAM) | ||
| JP2013510169A5 (OSRAM) | ||
| JP2017533201A5 (OSRAM) | ||
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| JP2017532343A5 (OSRAM) | ||
| JP2015504073A5 (OSRAM) | ||
| JP2016508123A5 (OSRAM) | ||
| RU2017124487A (ru) | НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом |